...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer
【24h】

Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer

机译：Eribulin促进局部晚期或转移性乳腺癌患者的抗肿瘤免疫反应

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: Several proteins involved in immune regulation and the relationship among these, the tumor microenvironment, and clinical outcomes of eribulin treatment were evaluated in advanced or metastatic breast cancer patients. Patients and Methods: This retrospective cohort study comprised 52 eribulin-treated locally advanced or metastatic breast cancer patients. Cancer tissue samples were obtained before and after treatment in 10 patients. Immunohistochemistry was performed to determine programmed death (PD)-1, CD8, and forkhead box P3 (FOXP3) expression by stromal tumor-infiltrating lymphocytes, and PD-ligand (L1) and PD-L2 expression by cancer cells. Results: Of the 10 patients, 5 were responders (partial response) and 5 were non-responders (stable disease, 2; progressive disease, 3) to eribulin. PD-1, PD-L2, and FOXP3 expression became negative in 5 patients, PD-L1 expression became negative in 6 patients, and CD8 expression became positive in 3 patients after treatment. The response to eribulin was significantly associated with PD-L1 and FOXP3 negative conversion (p=0.024 and 0.004, respectively). The change in E-cadherin expression (positive or negative) was also correlated with the changes in PD-L1 and FOXP3 (p=0.024 and 0.004, respectively). Kaplan-Meier analysis with log-rank tests revealed that progression free survival and time-to-treatment failure were significantly longer in patients with PD-L1 and FOXP3 negative conversion (p=0.012 and 0.001; p=0.049 and 0.018, respectively). Conclusion: The efficacy of eribulin may be attributed to its biological effects on the immune system (reduction of PD-Ll and FOXP3 expression) through epithelial-mesenchymal transition suppression, and vascular remodeling and improvement of the tumor microenvironment.
机译：背景/目的：在先进或转移性乳腺癌患者中评估了几种参与免疫调节的蛋白质，肿瘤微环境和纤维素治疗的临床结果。患者及方法：这种回顾性队列研究包括52个纤维素治疗的局部晚期或转移性乳腺癌患者。在10名患者治疗之前和之后获得癌症组织样品。进行免疫组织化学以确定通过基质肿瘤浸润淋巴细胞和PD-配体（L1）和PD-L2表达通过癌细胞测定编程死亡（Pd）-1，CD8和叉头箱P3（FoxP3）表达。结果：10例患者，5名患者（部分反应）和5例是非响应者（稳定疾病，2;渐进性疾病，3）。 PD-1，PD-L2和FoxP3表达在5名患者中变为负，PD-L1表达在6名患者中变为阴性，并且在治疗后3例患者CD8表达变为阳性。对Eribulin的反应显着与PD-L1和FoxP3负转化有关（分别为P = 0.024和0.004）。 E-Cadherin表达（阳性或阴性）的变化也与PD-L1和Foxp3的变化相关（分别分别为p = 0.024和0.004）。 Kaplan-Meier分析与日志秩检验显示，PD-L1和FOXP3负转化患者（P = 0.012和0.001分别）显着更长的患者可自由生存期和治疗时间衰竭显着更长。结论：Eribulin的疗效可以归因于通过上皮 - 间充质转换抑制和血管重构和肿瘤微环境的血管重塑和改善患者对免疫系统的生物学作用（降低PD-L1和Foxp3表达）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号